CClinicalTrials.gg
CompletedNCT03180632Endo-LoraUpdated Sep 5, 2018

Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:

A Phase 2 interventional study of Lorazepam and Placebo in Anxiety, sponsored by St. Justine's Hospital. Completed at 1 site in Canada. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by St. Justine's Hospital · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
9 Years to 18 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of a single dose of Lorazepam on salivary cortisol in children undergoing digestive endoscopy. To do so, the patients will be randomized in three groups. The first group receives the Lorazepam, the second group receives a placebo and the last group receives no intervention. Each patient will have three saliva samples taken at three different time point on the day of the endoscopy and will be asked to fill out questionnaires on anxiety and overall satisfaction of the procedure.

Read the detailed description

Background: Pediatric digestive endoscopies (gastroscopy and colonoscopy) are invasive procedures. All endoscopic procedure are conducted in the operating room either under intravenous (IV) sedation or general anesthesia. More than 50% of procedures are performed using IV sedation. The current sedation protocol in the endoscopy suite is a combination of Midazolam (0.1 mg/kg) and Fentanyl (1 microgram/kg) in all children. The children undergoing colonoscopies receive and additional administration of Ketamine (0.5 mg/kg).

In a previous study performed in children 10-18 years undergoing upper and lower endoscopy, the investigators found that despite this regimen, 25% of the children expressed a significantly high level of pain during endoscopy under IV sedation.

Because general anesthesia is not available for all children, it is important to investigate strategies that could help in minimizing the discomfort and pain during the procedure.

Salivary cortisol (sCortisol) has been used in several pediatric studies to determine the level of stress in children prior to various medical procedures. In another study done at our site, the investigators have found sCortisol to be a reliable biomarker of stress for children undergoing digestive endoscopies. Furthermore, the mean baseline sCortisol levels were higher in the group that experienced procedural pain.

Lorazepam is a a rapid onset benzodiazepine that has anxiolytic and sedative properties that has been approved by Health Canada as an adjunct therapy for the relief of excessive anxiety that might be present prior to surgical interventions.

Objective:

The primary objective is to investigate the effect of Lorazepam as compared to placebo on the change of the level of sCortisol between baseline (C1) and immediately before endoscopy (C2) in adolescents undergoing a gastroscopy or a colonoscopy. The investigators think that it might be possible to modulate the stress response with the administration of a benzodiazepine as soon as the children arrives at the hospital. Thus children could have a better experience of the digestive endoscopic procedure (less pain and more comfort).

The secondary outcome measure will be:

(1) the proportion of children experiencing procedural pain, (2) the duration of endoscopic procedures, (3) children satisfaction, (4) physician and nurse satisfaction (5) the total dose of Fentanyl and Ketamine per kilogram body weight delivered during the procedure and (6) the mean change between pre-op and postop cortisol levels between the two groups.

Safety outcomes measures: The following adverse events will be sought before and during the endoscopy: prolonged drowsiness, hypotension, hypertension, desaturation, bradycardia.

Exploratory outcomes: the mean change between pre-op and postop cortisol levels in the Group C (No intervention) compared to Group A and B.

Methods:

In this randomized controlled trial children will be assigned to one of the three following groups (no intervention, placebo and active drug). The investigators will collect salivary samples to measure the levels of sCortisol and investigate their variation between three timepoint ( at arrival at the hospital, right before the procedure and right after the procedure). sCortisol levels will be correlated to a questionnaire evaluating the anxiety level in the patient. The research team will also evaluate the pain experienced during the procedure using the Nurse-Assessed Patient Comfort Score (NAPCOMS): a validated tool for the evaluation of pain in subjects undergoing endoscopies).

02

Conditions studied

  • Anxiety
03

In context

Lead sponsor

St. Justine's Hospital is the lead sponsor of 155 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged 9-18 seen in our endoscopic unit
  • Children undergoing upper, lower or combined digestive endoscopy
  • Procedure to be performed within 3 hours of inclusion in the study and drug administration

Exclusion criteria

Exclusion Criteria:

  • Unable to read or speak English or French
  • Diagnosed with a psychiatric or neurological disorder
  • Myasthenia gravis
  • Acute narrow angle glaucoma
  • Known hypersensitivity to benzodiazepines
  • Already treated with an anxiolytic on a regular basis
  • Receiving a drug contraindicated in association with benzodiazepines
  • Receiving oral, intravenous or inhaled corticosteroids in the last two days before randomization
  • Body weight less than 20 kg
  • Pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Active comparator
    Group A

    Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.

    Drug: Lorazepam

  • Placebo comparator
    Group B

    Patient will receive a placebo similar in color, form and size.

    Other: Placebo

  • No intervention
    Group 3

    Patient will receive no intervention.

Interventions

  • DrugLorazepam

    Patient receives one or two tablet of 0,5mg Lorazepam according to body weight

    Also known as: Apo-Lorazepam

  • OtherPlacebo

    Patient receive one of two tablet of Placebo according to body weight

06

What researchers measure

Primary outcomes

  1. Change of sCortisol from baseline to one hour after drug administration

    Proportion of children with a decrease of sCortisol of at least 15 points between the group Placebo and the group Lorazepam

    Time frame: One hour after drug administration

Secondary outcomes

  1. Procedural pain

    Proportion of children experiencing procedural pain

    Time frame: during endoscopic procedure

  2. Duration of endoscopic procedure

    Duration of endoscopic procedure. The time interval in minutes will be measured between the start and the end of each procedure.

    Time frame: Through completion of endoscopy: an average of 2 hours after drug administration

  3. Children Satisfaction

    Children satisfaction will be evaluated with a validated Satisfaction questionnaire of children undergoing endoscopy

    Time frame: Through study completion, an average of 3 hours

  4. Physician Satisfaction

    Physician satisfaction will be evaluated with a validated tool : CLINICIAN SATISFACTION WITH SEDATION INSTRUMENT (CSSI)

    Time frame: during the endoscopic procedure

  5. Nurse Satisfaction

    Nurse satisfaction will be evaluated with a validated tool : NURSE ASSESSED PATIENT COMFORT SCORE (NAPCOMS)

    Time frame: during the endoscopic procedure

  6. Medication needed For sedation

    Total dose of Fentanyl and Ketamine per kilogram body weight delivered

    Time frame: during the procedure

  7. Change in sCortisol levels between pre-op and post-op

    Mean change between pre-op and post-op cortisol levels between the two groups (Lorazepam and Placebo)

    Time frame: one hour after the endoscopic procedure

Other outcomes

  1. Number of participants with Treatment-related Adverse Events (Safety and Tolerability)

    The following adverse events will be sought before and during the endoscopy: prolonged drowsiness, hypotension, hypertension, desaturation, bradycardia.

    Time frame: during the procedure

  2. Change in level of sCortisol between pre-op and post-op in the group without any intervention

    the mean change between pre-op and post-op cortisol levels in the Group C (No intervention)

    Time frame: Through study completion, an average of 3 hours

07

Study locations

1 site
  • CHU Sainte-Justine
    Montréal, Quebec H3T 1C5, Canada
08

References and documents

Publications

  • Chennou F, Bonneau-Fortin A, Portolese O, Belmesk L, Jean-Pierre M, Cote G, Dirks MH, Jantchou P. Oral Lorazepam is not Superior to Placebo for Lowering Stress in Children Before Digestive Endoscopy: A Double-Blind, Randomized, Controlled Trial. Paediatr Drugs. 2019 Oct;21(5):379-387. doi: 10.1007/s40272-019-00351-9. PubMed 31418168 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03180632
Lead sponsor
St. Justine's Hospital
Responsible party
Jantchou Prevost (MD,PhD, St. Justine's Hospital) — Principal investigator
First posted
Jun 8, 2017
Start date
Jun 28, 2017
Primary completion
Jun 1, 2018
Completion
Jun 1, 2018
Last update
Sep 5, 2018

Study contacts

Prévost Jantchou, MD, PhD
principal investigator · Ste-Justine Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion